An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

Trial Profile

An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs M 6620 (Primary) ; Cisplatin; Etoposide; Gemcitabine; Irinotecan
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors EMD Serono Research & Development Institute; Merck KGaA; Vertex Pharmaceuticals
  • Most Recent Events

    • 05 Jun 2018 Results (n=33) of dose expansion cohort of a phase I trial presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 09 May 2018 Planned End Date changed from 9 May 2019 to 18 Sep 2019.
    • 09 May 2018 Planned primary completion date changed from 9 May 2019 to 18 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top